Erva Ozkan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Erva Ozkan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Filiz Bakar-Ates
Department of Biochemistry, Faculty of Pharmacy, Ankara University, 06560 Ankara, Turkey
14 shared publications - Gokcen Eren
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330 Ankara, Türkiye
3 shared publications - Mahmut Gozelle
Gazi Üniversitesi
3 shared publications - Zubeyir Elmazoglu
Department of Pharmacology, Faculty of Pharmacy, Ankara Medipol University, Ankara, Turkey
3 shared publications - Alberto Massarotti
Dipartimento di Scienze del Farmaco Università degli Studi del Piemonte Orientale Novara Italy
2 shared publications - Selen Gozde Kaya
Department of Pharmaceutical Chemistry, SIRTeam Group, Faculty of Pharmacy Gazi University Ankara Türkiye
2 shared publications
Latest Publications
- 10 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1927
Exploiting redox vulnerability to sensitize glioblastoma cells to mirdametinib through oxidative damage and cell cycle re-programming
- 10 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1927
Exploiting redox vulnerability to sensitize glioblastoma cells to mirdametinib through oxidative damage and cell cycle re-programming
- 18 March 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (5) , 104319
The iron fist of nature: Cannabinoid derivatives alter iron homeostasis and activate ferroptotic pathways in glioblastoma cells
- 18 March 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (5) , 104319
The iron fist of nature: Cannabinoid derivatives alter iron homeostasis and activate ferroptotic pathways in glioblastoma cells
- Open Access
- 10 March 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70256
Structure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions
SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC 50 values in the micromolar range. To further optimize their activity, we performed molecular docking‐guided design and subsequent synthesis of a series of novel 1,3,4‐thiadiazole derivatives. SIRT inhibitory screening identified that ST131 and ST132 achieved moderate inhibitory effects against SIRT2 with IC 50 values of 8.95 and 6.62 µM, respectively. Moreover, cellular assays in MCF‐7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α‐tubulin expression levels, which is typically consistent with SIRT2 inhibition. In addition, docking studies were performed to analyze and rationalize the structural differences responsible for SIRT2 activity, shedding light on the importance of the interactions occurring at the entrance of the binding site. Finally, molecular mechanics‐generalized born surface area (MM‐GBSA) and molecular dynamics (MD) simulation approaches were conducted to verify the stability of ST132 in the complex with SIRT2.
- 10 March 2026
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70256
Open AccessStructure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions
SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC 50 values in the micromolar range. To further optimize their activity, we performed molecular docking‐guided design and subsequent synthesis of a series of novel 1,3,4‐thiadiazole derivatives. SIRT inhibitory screening identified that ST131 and ST132 achieved moderate inhibitory effects against SIRT2 with IC 50 values of 8.95 and 6.62 µM, respectively. Moreover, cellular assays in MCF‐7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α‐tubulin expression levels, which is typically consistent with SIRT2 inhibition. In addition, docking studies were performed to analyze and rationalize the structural differences responsible for SIRT2 activity, shedding light on the importance of the interactions occurring at the entrance of the binding site. Finally, molecular mechanics‐generalized born surface area (MM‐GBSA) and molecular dynamics (MD) simulation approaches were conducted to verify the stability of ST132 in the complex with SIRT2.
- Open Access
- 26 October 2025
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 7 (6) , 925-932
Rewiring chemotherapy response: venetoclax sensitizes human lung cancer cells to etoposide via enhanced DNA damage and ferroptotic pathways
Aims: Venetoclax is a selective Bcl-2 inhibitor small molecule, approved by FDA for acute myeloid and chronic lymphocytic leukemia. Despite the promising results in hematological malignancies, its therapeutic potential in lung cancer remains unclear. In the present study, the effect of conventional chemotherapeutics, etoposide and cisplatin, in combination with venetoclax was investigated along with the underlying mechanisms in lung cancer cells. Methods: Human non-small cell lung cancer cells (A549) were administered with cisplatin and etoposide either as single agents or in combination with venetoclax (8 µM), and the cell viability was determined with MTT assay. The acquired cytotoxicity was compared with L929 normal cells. ROS generation was visualized by confocal microscopy in the presence or absence of antioxidants (N-acetylcysteine, mannitol) and ferroptosis inhibitors (deferoxamine, ferrostatin-1). Furthermore, labile iron pool and lysosomal lipid were detected with Hoechst/Calcein-AM/Neutral red triple staining. Lipid peroxidation was determined with malondialdehyde assay. The mRNA expressions of DNA damage marker H2AX and ferroptotic marker transferrin were evaluated with RT-qPCR. Results: Results indicated that venetoclax (8 µM) sensitizes A549 cells to etoposide (p0.05). Further analyses demonstrated that co-treatment of etoposide and venetoclax significantly increased ROS generation, which was inhibited by ferroptosis inhibitors (p
- 26 October 2025
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 7 (6) , 925-932
Open AccessRewiring chemotherapy response: venetoclax sensitizes human lung cancer cells to etoposide via enhanced DNA damage and ferroptotic pathways
Aims: Venetoclax is a selective Bcl-2 inhibitor small molecule, approved by FDA for acute myeloid and chronic lymphocytic leukemia. Despite the promising results in hematological malignancies, its therapeutic potential in lung cancer remains unclear. In the present study, the effect of conventional chemotherapeutics, etoposide and cisplatin, in combination with venetoclax was investigated along with the underlying mechanisms in lung cancer cells. Methods: Human non-small cell lung cancer cells (A549) were administered with cisplatin and etoposide either as single agents or in combination with venetoclax (8 µM), and the cell viability was determined with MTT assay. The acquired cytotoxicity was compared with L929 normal cells. ROS generation was visualized by confocal microscopy in the presence or absence of antioxidants (N-acetylcysteine, mannitol) and ferroptosis inhibitors (deferoxamine, ferrostatin-1). Furthermore, labile iron pool and lysosomal lipid were detected with Hoechst/Calcein-AM/Neutral red triple staining. Lipid peroxidation was determined with malondialdehyde assay. The mRNA expressions of DNA damage marker H2AX and ferroptotic marker transferrin were evaluated with RT-qPCR. Results: Results indicated that venetoclax (8 µM) sensitizes A549 cells to etoposide (p0.05). Further analyses demonstrated that co-treatment of etoposide and venetoclax significantly increased ROS generation, which was inhibited by ferroptosis inhibitors (p
- 11 October 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (4) , 3985-3994
Synergistic ferroptosis in triple-negative breast cancer cells: Paclitaxel in combination with Erastin induced oxidative stress and Ferroportin-1 modulation in MDA-MB-231 cells
Ferroptosis is an important regulated cell death mechanism characterized by iron-dependent lipid peroxidation and oxidative stress. In this study, we examined the ferroptosis-inducing effect of the combined use of Paclitaxel, a microtubule-stabilizing agent, and Erastin, a ferroptosis inducer, in breast cancer cells. In this context, the combination of the compounds in question was applied to the cells and the presence of a synergistic effect was determined by calculating the combination index. Glutathione (GSH) levels and glutathione peroxidase (GPX) activity were determined by commercial assay kits, and the effect of the compounds on lipid peroxidation was determined by measurement of malondialdehyde (MDA) levels. Additionally, the effect of combination treatment on ferroptotic protein expression was determined by western blot. Our findings revealed that the combination treatment caused a significant change in mitochondrial function by causing an increase in the depolarized/viable cell population. Additionally, there was a significant increase in intracellular reactive oxygen species (ROS) levels compared to single applications of the compounds. The significant increase observed in malondialdehyde (MDA) levels revealed that the combination treatment increased lipid peroxidation. Moreover, intracellular GSH levels and glutathione peroxidase (GPX) activity significantly decreased by Paclitaxel-Erastin combination. The expression of ferroptosis-regulating proteins was significantly downregulated. The findings showed that the Paclitaxel-Erastin combination synergistically contributed to the accumulation of lipid reactive oxygen species and induced the ferroptotic cell death pathway in breast cancer cells.
- 11 October 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (4) , 3985-3994
Synergistic ferroptosis in triple-negative breast cancer cells: Paclitaxel in combination with Erastin induced oxidative stress and Ferroportin-1 modulation in MDA-MB-231 cells
Ferroptosis is an important regulated cell death mechanism characterized by iron-dependent lipid peroxidation and oxidative stress. In this study, we examined the ferroptosis-inducing effect of the combined use of Paclitaxel, a microtubule-stabilizing agent, and Erastin, a ferroptosis inducer, in breast cancer cells. In this context, the combination of the compounds in question was applied to the cells and the presence of a synergistic effect was determined by calculating the combination index. Glutathione (GSH) levels and glutathione peroxidase (GPX) activity were determined by commercial assay kits, and the effect of the compounds on lipid peroxidation was determined by measurement of malondialdehyde (MDA) levels. Additionally, the effect of combination treatment on ferroptotic protein expression was determined by western blot. Our findings revealed that the combination treatment caused a significant change in mitochondrial function by causing an increase in the depolarized/viable cell population. Additionally, there was a significant increase in intracellular reactive oxygen species (ROS) levels compared to single applications of the compounds. The significant increase observed in malondialdehyde (MDA) levels revealed that the combination treatment increased lipid peroxidation. Moreover, intracellular GSH levels and glutathione peroxidase (GPX) activity significantly decreased by Paclitaxel-Erastin combination. The expression of ferroptosis-regulating proteins was significantly downregulated. The findings showed that the Paclitaxel-Erastin combination synergistically contributed to the accumulation of lipid reactive oxygen species and induced the ferroptotic cell death pathway in breast cancer cells.
- Open Access
- 12 June 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (4) , e22224
2‐(Methyl(phenyl)amino)‐N‐(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition
The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD+‐dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (ST61‐ST90) by the structural optimization of our hit STH2, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, ST72, ST85, and ST88 selectively inhibited SIRT2 with IC50 values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by in silico prediction of binding modes of docked compounds and the stability of SIRT2‐ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.
- 12 June 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (4) , e22224
Open Access2‐(Methyl(phenyl)amino)‐N‐(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition
The mammalian cytoplasmic protein SIRT2, a class III histone deacetylase family member, possesses NAD+‐dependent lysine deacetylase/deacylase activity. Dysregulation of SIRT2 has been implicated in the pathogenesis of several diseases, including neurological and metabolic disorders and cancer; thus, SIRT2 emerges as a potential therapeutic target. Herein, we identified a series of diaryl acetamides (ST61‐ST90) by the structural optimization of our hit STH2, followed by enhanced SIRT2 inhibitory potency and selectivity. Among them, ST72, ST85, and ST88 selectively inhibited SIRT2 with IC50 values of 9.97, 5.74, and 8.92 μM, respectively. Finally, the entire study was accompanied by in silico prediction of binding modes of docked compounds and the stability of SIRT2‐ligand complexes. We hope our findings will provide substantial information for designing selective inhibitors of SIRT2.
- 11 November 2023
- Published by Elsevier in Toxicology in Vitro
- Vol. 94, 105732
Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation
- 11 November 2023
- Published by Elsevier in Toxicology in Vitro
- Vol. 94, 105732
Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation
- 16 October 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (19) , 1-8
Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma
Copper is an essential element for critical cellular functions such as mitochondrial respiration, cholesterol biosynthesis and immune response. Altered copper homeostasis has been associated with various disorders, including cancer. The copper overload is known to contribute to tumorigenesis, angiogenesis and metastasis, and recently it has been suggested that the elevated level of this element may also create vulnerability to a novel cell death mechanism, named cuproptosis. Excessive amount of copper in mitochondria binds to lipoylated enzymes of the TCA cycle and forms insoluble oligomers. The aggregation of these oligomers and subsequent iron–sulfur cluster protein loss results in proteotoxic stress and eventual cell death. Hepatocellular carcinoma is a common malignancy with a low survival rate, despite the available treatment options. The discovery of cuproptosis led many researchers to explore its potential use in hepatocellular cancer therapy due to the rich mitochondria content of hepatic cells. In this regard, a number of genomic studies were conducted to discover several cuproptosis-related genes and explored their association with prognosis, survival and immunotherapy response. This review brings together the available data on the relationship between cuproptosis and hepatocellular cancer for the first time, and highlights some of the potential biomarkers or target molecules that may be useful in the treatment.
- 16 October 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (19) , 1-8
Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma
Copper is an essential element for critical cellular functions such as mitochondrial respiration, cholesterol biosynthesis and immune response. Altered copper homeostasis has been associated with various disorders, including cancer. The copper overload is known to contribute to tumorigenesis, angiogenesis and metastasis, and recently it has been suggested that the elevated level of this element may also create vulnerability to a novel cell death mechanism, named cuproptosis. Excessive amount of copper in mitochondria binds to lipoylated enzymes of the TCA cycle and forms insoluble oligomers. The aggregation of these oligomers and subsequent iron–sulfur cluster protein loss results in proteotoxic stress and eventual cell death. Hepatocellular carcinoma is a common malignancy with a low survival rate, despite the available treatment options. The discovery of cuproptosis led many researchers to explore its potential use in hepatocellular cancer therapy due to the rich mitochondria content of hepatic cells. In this regard, a number of genomic studies were conducted to discover several cuproptosis-related genes and explored their association with prognosis, survival and immunotherapy response. This review brings together the available data on the relationship between cuproptosis and hepatocellular cancer for the first time, and highlights some of the potential biomarkers or target molecules that may be useful in the treatment.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 59, e22330
Investigation on formulation parameters of donepezil HCl loaded solid lipid nanoparticles
Donepezil-HCl is a member of the acetylcholinesterase inhibitors that is indicated for the symptomatic treatment of Alzheimer’s disease (AD) and has many side effects. In this study, to reduce the side effects of Donepezil-HCl and increase the penetration of the drug through the blood-brain barrier, we aimed to design a solid lipid nanoparticle (SLN) formulation. The effects of the different formulation parameters, such as homogenization speed, sonication time, lipid and drug concentration, surfactant type and concentration, and volume of the aqueous phase, were assessed for optimization. The particle size and PDI increased with increasing lipid concentration but decreased with increasing amounts of surfactant (Tween 80) and co-surfactant (lecithin). When the homogenization rate and sonication time increased, the particle size decreased and the encapsulation efficiency increased. The optimized formulation exhibited particle size, PDI, encapsulation efficiency, and zeta potential of 87.2±0.11 nm; 0.22±0.02; 93.84±0.01 %; -17.0±0.12 mV respectively. The in vitro release investigation revealed that approximately 70% of Donepezil-HCl was cumulatively released after 24 hours. TEM analysis proved that spherical and smooth particles were obtained and formulations had no toxic effect on cells. The final optimized formulation could be a candidate for Donepezil-HCl application in Alzheimer’s treatment with reduced side effects and doses for patients.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 59, e22330
Open AccessInvestigation on formulation parameters of donepezil HCl loaded solid lipid nanoparticles
Donepezil-HCl is a member of the acetylcholinesterase inhibitors that is indicated for the symptomatic treatment of Alzheimer’s disease (AD) and has many side effects. In this study, to reduce the side effects of Donepezil-HCl and increase the penetration of the drug through the blood-brain barrier, we aimed to design a solid lipid nanoparticle (SLN) formulation. The effects of the different formulation parameters, such as homogenization speed, sonication time, lipid and drug concentration, surfactant type and concentration, and volume of the aqueous phase, were assessed for optimization. The particle size and PDI increased with increasing lipid concentration but decreased with increasing amounts of surfactant (Tween 80) and co-surfactant (lecithin). When the homogenization rate and sonication time increased, the particle size decreased and the encapsulation efficiency increased. The optimized formulation exhibited particle size, PDI, encapsulation efficiency, and zeta potential of 87.2±0.11 nm; 0.22±0.02; 93.84±0.01 %; -17.0±0.12 mV respectively. The in vitro release investigation revealed that approximately 70% of Donepezil-HCl was cumulatively released after 24 hours. TEM analysis proved that spherical and smooth particles were obtained and formulations had no toxic effect on cells. The final optimized formulation could be a candidate for Donepezil-HCl application in Alzheimer’s treatment with reduced side effects and doses for patients.
- 29 November 2022
- Published by Springer Nature in Medical Oncology
- Vol. 40 (1) , 1-8
Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells
Matrix metalloproteinases (MMPs) are a family of endopeptidases, mainly responsible of extracellular tissue remodeling. Abundant expression of MMPs leads to a number of tumorigenic processes including proliferation, angiogenesis, metastasis and invasion. Therefore, suppressing MMP expression is particularly important in cancer. Atorvastatin is a member of statin family, with cholesterol-lowering properties. Recently, it has emerged as a potential anticancer agent. Multiple researchers have reported promising results of atorvastatin use in cancer therapies. However, its effect on the expression of matrix metalloproteinases in breast cancer is unknown. In the present study, we have confirmed the apoptotic activity of atorvastatin on highly metastatic MDA-MB-231 triple negative breast cancer cells and investigated the gene expression of MMP-2/9. In this regard, MTT analysis was performed to evaluate cytotoxicity. Apoptotic activity was assessed by Annexin V binding and multicaspase assays. Western blot analysis was used to detect the apoptosis-related proteins. RT-PCR analysis was performed to evaluate the mRNA expression levels of MMP-2/9. Results indicated that atorvastatin reduces cell viability significantly at 5 µM after 48 h of treatment (p < 0.0001). It also induces caspase-dependent apoptosis, alters the expression of Bax and Bcl-2 in favour of apoptosis and stimulates cell cycle arrest at S phase (p < 0.05). Moreover, atorvastatin downregulates the mRNA expression of MMP-2 and MMP-9 significantly (p < 0.05). In conclusion, these results demonstrate for the first time that atorvastatin inhibits MMP-2 and MMP-9 gene expression in MDA-MB-231 cells, in addition to inducing caspase-dependent apoptosis.
- 29 November 2022
- Published by Springer Nature in Medical Oncology
- Vol. 40 (1) , 1-8
Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells
Matrix metalloproteinases (MMPs) are a family of endopeptidases, mainly responsible of extracellular tissue remodeling. Abundant expression of MMPs leads to a number of tumorigenic processes including proliferation, angiogenesis, metastasis and invasion. Therefore, suppressing MMP expression is particularly important in cancer. Atorvastatin is a member of statin family, with cholesterol-lowering properties. Recently, it has emerged as a potential anticancer agent. Multiple researchers have reported promising results of atorvastatin use in cancer therapies. However, its effect on the expression of matrix metalloproteinases in breast cancer is unknown. In the present study, we have confirmed the apoptotic activity of atorvastatin on highly metastatic MDA-MB-231 triple negative breast cancer cells and investigated the gene expression of MMP-2/9. In this regard, MTT analysis was performed to evaluate cytotoxicity. Apoptotic activity was assessed by Annexin V binding and multicaspase assays. Western blot analysis was used to detect the apoptosis-related proteins. RT-PCR analysis was performed to evaluate the mRNA expression levels of MMP-2/9. Results indicated that atorvastatin reduces cell viability significantly at 5 µM after 48 h of treatment (p < 0.0001). It also induces caspase-dependent apoptosis, alters the expression of Bax and Bcl-2 in favour of apoptosis and stimulates cell cycle arrest at S phase (p < 0.05). Moreover, atorvastatin downregulates the mRNA expression of MMP-2 and MMP-9 significantly (p < 0.05). In conclusion, these results demonstrate for the first time that atorvastatin inhibits MMP-2 and MMP-9 gene expression in MDA-MB-231 cells, in addition to inducing caspase-dependent apoptosis.